➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Dow
Boehringer Ingelheim
Moodys
AstraZeneca

Last Updated: July 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,122,566


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,122,566 protect, and when does it expire?

Patent 7,122,566 protects SKELAXIN and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 7,122,566
Title:Metaxalone products, method of manufacture, and method of use
Abstract:Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
Inventor(s): Du; Jie (Lansdale, PA), Roberts; Richard H. (Lakewood, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:11/364,468
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,122,566
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,122,566

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF MUSCULOSKELETAL CONDITIONS ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,122,566

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2626027 ⤷  Try it Free
World Intellectual Property Organization (WIPO) 2007094825 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Mallinckrodt
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.